Karyopharm (KPTI) insider: PSUs vest on SENTRY enrollment; small tax-driven sale

Rhea-AI Filing Summary

Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics Inc. (KPTI), reported the vesting of performance-based restricted stock units and a small subsequent sale. On September 12, 2025 the company certified that the clinical milestone for complete enrollment in its Phase 3 SENTRY trial had been achieved, resulting in 46 earned PSUs (each convertible into one share) which vested that day. The reporting line shows 10,431 shares beneficially owned following vesting (including 922 shares acquired via the ESPP on April 30, 2025). On September 15, 2025 the reporting person sold 23 shares at $6.43 per share under a pre-established automatic sale instruction to satisfy tax withholding obligations.

Insights

Financial Analyst

TL;DR: Routine insider vesting and tax-driven sale tied to a certified clinical trial enrollment milestone.

The filing documents the conversion of 46 performance-based RSUs into vested shares following certification that the Phase 3 SENTRY trial reached complete enrollment. That operational milestone is company-identified and triggered the PSU payout; the insider retained the vast majority of shares and executed a small, non-discretionary sale of 23 shares at $6.43 to cover withholding taxes. For investors, this is an administrative insider event rather than a directional trading signal.

Corporate Governance Expert

TL;DR: Proper disclosure of vested PSUs and a pre-arranged sale plan demonstrates standard governance and tax compliance.

The filing indicates the Compensation Committee certified a clinical enrollment milestone that materially satisfied vesting conditions for performance RSUs awarded in February 2023. The sale of a small number of shares was executed under a previously adopted durable automatic sale instruction, which the filing discloses. The form is complete, signed by an attorney-in-fact, and follows required Section 16 reporting conventions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Abate Kristin

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MA 02459

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/12/2025		A		46(1)	A	$0.0	10,431(2)	D
Common Stock	09/15/2025		S(3)		23	D	$6.43	10,408	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 SENTRY trial, as certified by the issuer's Compensation Committee on September 12, 2025. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on September 12, 2025.

2. Includes 922 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan on April 30, 2025.

3. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.

	/s/ Nancy Smith as Attorney-in-Fact for Kristin Abate	09/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Kristin Abate (KPTI) report?

The filing reports the vesting of 46 PSUs on September 12, 2025 and a sale of 23 shares on September 15, 2025 at $6.43 per share.

Why did Kristin Abate sell 23 shares on September 15, 2025?

The sale was executed under a durable automatic sale instruction to satisfy the withholding tax liability incurred upon PSU vesting; it was not a discretionary trade.

What triggered the PSU vesting reported on Form 4 for KPTI?

The PSUs were earned based on achievement of the clinical milestone for complete enrollment in the Phase 3 SENTRY trial, as certified by the Compensation Committee on September 12, 2025.

How many KPTI shares did Kristin Abate own after the transactions?

The filing shows 10,431 shares beneficially owned following the reported transactions.

Does the filing indicate any discretionary insider trading activity?

No. The reported sale was executed pursuant to a pre-established automatic sale instruction adopted on May 27, 2021.